Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically proven soft tissue sarcoma, glioma, mesothelioma, hepatoma, thyroid cancer, or adrenal cancer with clinical, radiological, or histologic evidence of incurability
• Patients with thyroid cancer must have failed radioactive iodine
• Measurable or evaluable disease
• PATIENT CHARACTERISTICS:
• Age:
• 65 and under
• Performance status:
• ECOG 0-2
• Hematopoietic:
• Granulocyte count at least 1,500/mm3
• Platelet count at least 140,000/mm3
• Hepatic:
• Bilirubin normal
• Renal:
• Creatinine less than 1.47 mg/dL
• Cardiovascular:
• Left ventricular ejection fraction at least 50% by MUGA scan
• No congestive heart failure
• No severe, uncontrolled hypertension
• No ischemia, life-threatening arrhythmia, or conduction disturbance by ECG
• Other:
• No allergy to study medications
• No uncontrolled infection
• No active abuse of ethanol that would preclude treatment
• No other prior or concurrent malignancy
• Not pregnant
• Fertile patients must use effective contraception
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• Not specified
• Chemotherapy:
• No more than 1 prior chemotherapy regimen
• No prior anthracycline or cisplatin
• At least 3 weeks since other prior chemotherapy and recovered
• Endocrine therapy:
• Not specified
• Radiotherapy:
• See Disease Characteristics
• No prior radiotherapy to more than 25% of bone marrow
• At least 3 weeks since other prior radiotherapy and recovered
• Surgery:
• Not specified